Drug profile · INN
ipragliflozin l-proline
SUGLAT INITIAL APPROVAL
ipragliflozin l-proline (SUGLAT INITIAL APPROVAL) is a sodium/glucose cotransporter 2 inhibitor.
PMDA: approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — ipragliflozin l-proline
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.78
Quick answer
ipragliflozin l-proline (SUGLAT INITIAL APPROVAL) is a sodium/glucose cotransporter 2 inhibitor.
Key facts
INN ipragliflozin l-proline
Brand SUGLAT INITIAL APPROVAL
Mechanism Sodium/glucose cotransporter 2 inhibitor
Target Sodium/glucose cotransporter 2
Mechanism of action
Sodium/glucose cotransporter 2 inhibitor
Primary target: Sodium/glucose cotransporter 2
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ipragliflozin l-proline?
ipragliflozin l-proline (SUGLAT INITIAL APPROVAL) is a sodium/glucose cotransporter 2 inhibitor.
What is the brand name for ipragliflozin l-proline?
SUGLAT INITIAL APPROVAL is a marketed brand name for ipragliflozin l-proline. Check FDA Drugs@FDA for the current US label holder and prescribing information.